FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer
On December 18, 2019, the U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (PadcevTM) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
- Read more about FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer
- Add new comment
Two ONS Health Policy Priorities Pass the House, Thanks to 2019 Capitol Hill Days
Participants in ONS’s Fourth Annual Capitol Hill Days quickly saw the fruits of their efforts when two ONS priority bills were passed in the U.S. House of Representatives in October 2019. The yearly advocacy, education, and training event, held September 22–24, brought 110 ONS activists to Washington, DC, for two days of sessions, briefings, updates, and meetings. The advocates engaged in 55 hours of intensive political and policy analysis, enabling them to take the Society’s health policy priority agenda to the U.S. Congress and help transform the future of health care in the United States.
- Read more about Two ONS Health Policy Priorities Pass the House, Thanks to 2019 Capitol Hill Days
- Add new comment
Combining Tamoxifen and Blue Light Can Better Target CAR T Cells
Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.
FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi®) for patients with metastatic castration-sensitive prostate cancer.
- Read more about FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
- Add new comment
The Case Supporting the Seasons of Survivorship
Jamie is completing her last cycle of carboplatin and paclitaxel for stage I ovarian cancer. The oncology infusion nurse notices that Jamie appears withdrawn and nervous, so he takes time to ask her how she is feeling about completing treatment. Jamie responds, “I feel as frightened about finishing treatment as I did when I was diagnosed with cancer.” She also shares that she doesn’t want to ring the cancer center’s bell to ceremoniously signify the end of her treatment because she doesn’t want to “jinx it.”
Bill to Lower Drug Costs; Surprise Medical Billing; The Fight Against Vaping
The Elijah E. Cummings Lower Drug Costs Now Act of 2019, otherwise known as H.R. 3, is a top priority for House Speaker Nancy Pelosi (D-CA). But she’s facing challenges from progressive Democrats on her left more so than the conservative Senate on her right. Watering down provisions in H.R. 3 too much will lose her the votes she needs to pass the bill in the House, but passing a bill that’s too overarching or progressive will allow Senate Majority Leader Mitch McConnell (R-KY) to refuse to take up the legislation at all.
- Read more about Bill to Lower Drug Costs; Surprise Medical Billing; The Fight Against Vaping
- Add new comment
Oncology Nursing Foundation Welcomes New Executive Director
For more than 35 years, the Oncology Nursing Foundation has been devoted to supporting cancer nursing excellence. To steward those efforts in the years to come, the Foundation welcomes Anizia Karmazyn as its new executive director. Karmazyn will work with Foundation Board of Trustees, Linda Worrall, RN, MSN, the Foundation’s director of grants and program, and other Foundation staff to Increase support for oncology nursing education, research, and leadership development.
Our Decade of Progress Continues in the Years Ahead
ONS Chapters Answer the Call on Giving Tuesday
After busy Thanksgiving get-togethers and frantic Black Friday, Small-Business Saturday, and Cyber Monday shopping, many people take a moment to reflect and give back to a cause that captures their passion. Dubbed Giving Tuesday, it’s a day dedicated to philanthropy and fundraising. For the first time ever, the Oncology Nursing Foundation issued a Giving Tuesday challenge to ONS chapters—a friendly competition to see which group could get the highest percentage of its membership to donate to the continued growth and excellence of oncology nursing. When all was said and done, 30 ONS chapters helped raise more than $19,000 to support the education, research, and leadership development of oncology nurses everywhere.
Newer Therapies at Last Offer Systemic Options for Metastatic HCC
Already the third leading cause of cancer deaths worldwide, hepatocellular carcinoma (HCC) is a continually growing burden as the incidence of obesity, type II diabetes, and hypertension also increase, which may lead to cirrhosis and nonalcoholic fatty liver disease. Its incidence is highest in Asia and Africa, where the prevalence of hepatitis B and hepatitis C may result in chronic liver disease and subsequently HCC.